Genomic Tests Eliminate ‘Diagnostic Odysseys’ ̶ Why Are They Underutilized In The UK?
Executive Summary
Genomic diagnostics provide significant value to the health system, but England’s unclear funding pathways and commissioning processes are preventing these tests from reaching patients, a report by trade body BIVDA reveals.
You may also be interested in...
UK Diagnostics Companies Count On Medtech Strategy To Deliver
The UK government’s first ever medtech strategy has received plaudits for its ambition. The diagnostics industry, while supportive of the intent, is waiting for more than just promises.
Innovative Diagnostic For Babies Wins NICE Early Value Assessment Pilot Backing
An innovative genetic test that can detect which babies are likely to develop deafness if treated with a common antibiotic is set to receive conditional funding in the UK under NICE’s rapid evaluation pilot scheme.
UK Diagnostic Capacity And Spending Below European Average
The UK’s diagnostics sector has faced “significant underinvestment” over recent years, according to researchers at health think tank The King’s Fund. A new report shows how the UK’s spending on diagnostics compares to other European countries.